The Remedy Room — Legislation
Legislation We Are Watching
Three bills. Three failure modes addressed. S.3829 punishes the executives. S.3822 breaks up the structure. H.R. 6852 establishes the clinical right. None of them alone closes the loop — but together, they form the first coherent legislative architecture for dismantling the Wrongful Denial Echo Chamber.
Bills
The Legislative Architecture
The Wrongful Denial Echo Chamber is not a single problem - it is an interlocking system of failures. Dismantling it requires interlocking solutions. Below is the complete framework, with each piece of legislation named, its function explained, and its relationship to the others.
S.3829 is the sword.
Criminal and civil penalties for executives whose decisions cause patient harm. Unjust enrichment clawbacks. The force of law aimed at the corporation.
The Clinical Integrity Amendment is the shield.
Mandatory State Medical Board referral when an IRE overturn proves Prior Knowledge Omission. The personal accountability that S.3829 doesn't reach — stripping the license from the physician who pulled the trigger.
The Buffer Fund is the refuge.
Capitalized by S.3829's 500% clawback penalties, it provisionally covers denied care during appeal — so patients are not forced to survive the delay while their condition deteriorates. The insurer funds the safety net their denials necessitate.
The Department of Recovery is the courthouse.
A federally-staffed Recovery Coordination Office to absorb IRE overflow, aggregate pattern data that converts individual fraud into prosecutable systemic fraud, and administer the mandatory board reporting pipeline the Amendment requires.
H.R. 6852 is the clinical floor.
It establishes that FDA-approved wound care treatments are covered Medicare benefits. Without it, the enforcement mechanisms above have no clinical standard to enforce. Without S.3829 and the Amendment, H.R. 6852 is a payment rule insurers can still delay and deny around.
§ 6 is the endowment.
The Buffer Fund's long-term sustainability architecture — industry-funded seed capitalization, an endowment layer that generates perpetual yield, and dynamic multiplier scaling tied to the Department of Recovery's annual data. When fraud falls, the fund doesn't collapse. It proves the reform worked.
S.3829 — Corporate Crimes Against Healthcare Act
Sponsors: Sen. Elizabeth Warren (for herself, Sen. Blumenthal, Sen. Markey, Sen. Merkley, and Sen. Welch)
The Corporate Crimes Against Healthcare Act targets the executives and corporate structures that profit from patient harm. It creates the enforcement mechanism that makes wrongful denial a crime with real consequences — not just a line item in a settlement.
- Unjust Enrichment Clawback: If a healthcare company experiences a "triggering event" — patient harm, bankruptcy, or fraud — the Attorney General or any State AG may claw back all covered compensation received by executives during the preceding or succeeding 10 years.
- Criminal Penalty: Any covered party whose actions contributed to a triggering event that results in the death or injury of a patient faces 1–6 years imprisonment.
- Civil Penalty: Up to 5 times the amount of any clawback authorized — creating the 500% penalty that capitalizes the Patient Safety Buffer Fund.
- Mandatory Ownership Transparency: Requires specified healthcare entities to annually report mergers, acquisitions, ownership changes, and financial structures — with a $5,000,000 penalty for false or missing reports.
- Moral Injury Study: Requires the HHS Inspector General to evaluate profit-driven practices in healthcare delivery and report to Congress — including prior authorization abuse, upcoding, AI-driven denials, and insurers' efforts to evade state corporate practice of medicine laws.
The gap S.3829 leaves open: S.3829 punishes the corporation and its executive leadership. It does not reach the individual physician who signs the denial letter — the medical director who excludes qualifying clinical data on procedural pretexts and faces no personal accountability for the harm that follows. That gap is precisely what the Clinical Integrity Amendment closes.
The cases S.3829 would have resolved → Room I
The Ballad Health lawsuit, the Lokken estate class action, the Senate investigation — documented in The Problem Room.
Legal Challenges & Lawsuits →S.3822 — Break Up Big Medicine Act
Sponsors: Sen. Elizabeth Warren and Sen. Josh Hawley — one of the most politically unlikely alliances in recent legislative history, united by what the bill's findings call "an unprecedented wave of consolidation."
The fact that Warren and Hawley are co-sponsors of the same healthcare bill tells you something important: the structural corruption of vertical integration in healthcare is not a partisan issue. It is a market capture issue. The left sees patient exploitation. The right sees monopoly. Both are correct. The bill exists because both diagnoses point to the same cure.
What It Does
The Break Up Big Medicine Act makes it unlawful for any person to simultaneously own or control both a healthcare provider (or management services organization) and an insurance company, pharmacy benefit manager, or prescription drug wholesaler. Companies in violation have one year to divest.
- Structural Separation: Prohibits common ownership of insurers or PBMs with medical providers. Prohibits common ownership of drug wholesalers with medical providers. The vertical integration that created UHG's empire — insurer + PBM + physician employer + data infrastructure — becomes illegal.
- Hard Divestment Deadline: One year from enactment. Non-compliance triggers an automatic 10% monthly profit escrow, held until divestment occurs. If divestment still doesn't happen, a court-appointed trustee executes the sale.
- Private Right of Action: Individual patients harmed by violations can sue directly — and may recover treble damages plus attorney's fees. This is not a waiting-for-the-government mechanism. Patients can be the enforcement arm.
- FTC + DOJ Joint Enforcement: Both agencies have concurrent jurisdiction to bring civil actions. State attorneys general can also sue as parens patriae on behalf of state residents.
- Disgorgement: Courts may order companies to disgorge all revenue received from entities subject to divestment during the period of violation — not just fines, but stripping the profit from the illegal structure retroactively.
- Quarterly Congressional Reporting: The FTC and DOJ must submit quarterly compliance reports to Congress — creating an ongoing public accountability mechanism.
- Future Blocking Authority: FTC and DOJ gain explicit authority to block any future action that would recreate the prohibited conflicts of interest — closing the re-acquisition loophole.
Congressional Findings (from the Bill Text)
- As of 2023, one conglomerate controls approximately 10% of all American physicians — the single largest employer of physicians in the nation.
- More than three-quarters of all American doctors are now employed by corporate entities.
- The 3 largest PBMs process nearly 80% of all prescription drug claims.
- The 3 largest drug wholesalers control 98% of the U.S. drug distribution market.
- The FTC has found that vertically integrated PBMs have both the ability and incentive to steer business to their own affiliated pharmacies, reducing competition and increasing drug costs.
- Private insurers use employed physicians to intensively document enrollees' medical conditions — generating inflated payments from the Federal government without improving care quality. (The upcoding mechanism, confirmed in the bill's own findings.)
The market conditions S.3822 addresses → Room I
Mayo Clinic exits. LVHN patients displaced. Optum reshuffling. The documented consequences of vertical integration.
Market Power & Hospital Conflicts →H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act
Sponsor: Rep. Evans of Colorado
Why This Bill Is Personal
Apligraf — an FDA-approved skin substitute product (PMA P950032S016, cleared 2000) — was denied by UnitedHealthcare for 17 months while non-healing wounds progressed to bone demineralization described as "cuttable with a scalpel." When Apligraf was finally approved, it closed those wounds in two weeks. H.R. 6852 directly addresses the payment and coverage framework for products like Apligraf under Medicare. The Denial on Trial framework names this bill explicitly: H.R. 6852 addresses the clinical harm. The Clinical Integrity Amendment and S.3829 provide the enforcement mechanism that gives it teeth.
📋 What the FDA Said — Starting in 1995
The following facts are drawn directly from the FDA's Summary of Safety and Effectiveness Data for Apligraf® (PMA P950032, Supplement S016). This is not advocacy. This is the federal regulatory record.
Aug 7, 1995
FDA authorized expedited review based on Apligraf's potential to provide "a clinically important advance over existing alternatives" for neuropathic diabetic foot ulcers. The urgency was recognized 25 years before UHC's denial.
May 22, 1998
FDA approved Apligraf for venous leg ulcers — skin ulcers due to venous insufficiency of greater than 1 month duration that have not adequately responded to conventional therapy. Exactly the indicated use UHC denied.
June 20, 2000
FDA approved Apligraf for diabetic foot ulcers following a prospective, randomized, multi-center controlled clinical trial. Full federal approval issued. Standard of care established.
2018–2019
UnitedHealthcare denied Apligraf for 17 months — 18–21 years after federal approval — while wounds progressed to bone demineralization. When finally approved, the wounds closed in two weeks.
The Clinical Trial Data UHC Ignored
The FDA's pivotal trial (Protocol 95-DUS-001, n=208 patients) demonstrated results confirmed and refined by the manufacturer's ongoing real-world evidence program:
- 56.3% wound closure for Apligraf patients vs 37.5% for control at 12 weeks (p=0.0082)
- Median time to 50% wound closure: 65 days for Apligraf vs 90 days for control (p=0.0026)
- Amputation incidence at 6 months: 6.3% vs 15.6% for control (p=0.028) — Apligraf reduces amputation risk by roughly 60%
- Osteomyelitis incidence at 6 months: 2.7% vs 10.4% for control (p=0.04) — Apligraf reduces bone infection risk by roughly 75%
- No immune rejection observed in any patient. No antibody responses against bovine collagen or human cell components.
Note: The 2000 FDA approval data has since been further validated by the manufacturer's real-world evidence program using large-scale EMR databases. The efficacy profile has strengthened, not weakened, with 25 years of post-market use. The case against the denial gets stronger over time, not weaker.
UHC denied a treatment the FDA recognized as a "clinically important advance" in 1995, approved in 1998 and 2000, that reduces amputation risk by 60% and bone infection risk by 75% in clinical trials — citing it as "not medically necessary" for 17 months. The patient subsequently developed osteomyelitis severe enough that bone was described as "cuttable with a scalpel." The treatment was proven to prevent that exact outcome. When it was finally approved, wounds closed in two weeks.
What It Does
H.R. 6852 reforms how Medicare covers and pays for skin substitute products — cellular, tissue, biological, or synthetic materials applied to wounds and intended to remain in the wound bed. This includes advanced wound treatments like Apligraf that have been FDA-cleared and standard-of-care for decades but remain subject to arbitrary insurance denial and delayed access.
- Medicare Coverage Established: Formally adds skin substitute products as a covered Medicare benefit under Section 1861(s)(2) of the Social Security Act — closing the ambiguity that allows insurers to deny FDA-approved wound treatments as "experimental" or "not medically necessary."
- Standardized Payment: Creates a volume-weighted average payment methodology based on 2023 Medicare data, with annual CPI adjustments — replacing the current pricing chaos that enables over- and under-payment alike. Effective January 1, 2026.
- Site-of-Care Parity: Requires equivalent reimbursement for skin substitute products regardless of the care setting — preventing the practice of denying outpatient access to treatments that would be covered in a hospital setting.
- Program Integrity: Identifies the top 3% of skin substitute product billers as "outlier providers" and requires CMS to conduct prepayment review and, where warranted, prior authorization — targeting fraudulent billing on the provider side while protecting legitimate patient access.
- FDA Streamlining: Directs FDA to conduct a comprehensive review within 18 months of the approval processes for human cellular and tissue allografts — with specific attention to tiered risk frameworks, streamlined application requirements, and reduced duplicative clinical trial burdens. Guidance to be finalized within 36 months.
- Congressional Accountability: Requires a report to the Senate HELP Committee and House Energy & Commerce Committee on findings, recommendations, and estimated patient access impacts.
The Legislative Architecture Connection
H.R. 6852 establishes the clinical right — that FDA-approved wound care treatments are covered Medicare benefits with predictable payment. S.3829 and the Clinical Integrity Amendment establish the enforcement mechanism — that a physician who denies a covered, medically necessary treatment faces license consequences. Without H.R. 6852, the enforcement mechanism has no clinical standard to enforce. Without S.3829 and the Amendment, H.R. 6852 is a payment rule that insurers can still delay, deny, and appeal around.